MaxCyte Inc (NASDAQ: MXCT) kicked off on Monday, down -5.56% from the previous trading day, before settling in for the closing price of $3.42. Over the past 52 weeks, MXCT has traded in a range of $3.23-$5.55.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 20.83% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded -11.97%. With a float of $97.34 million, this company’s outstanding shares have now reached $103.96 million.
In an organization with 143 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 79.04%, operating margin of -101.56%, and the pretax margin is -78.36%.
MaxCyte Inc (MXCT) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Medical Devices Industry. The insider ownership of MaxCyte Inc is 7.72%, while institutional ownership is 68.11%. The most recent insider transaction that took place on Nov 01 ’24, was worth 177,403. In this transaction Director of this company sold 47,689 shares at a rate of $3.72, taking the stock ownership to the 269,118 shares. Before that another transaction happened on Oct 28 ’24, when Company’s Director sold 3,000 for $3.72, making the entire transaction worth $11,166. This insider now owns 141,950 shares in total.
MaxCyte Inc (MXCT) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -11.97% per share during the next fiscal year.
MaxCyte Inc (NASDAQ: MXCT) Trading Performance Indicators
Take a look at MaxCyte Inc’s (MXCT) current performance indicators. Last quarter, stock had a quick ratio of 9.22. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.43.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.34, a number that is poised to hit -0.12 in the next quarter and is forecasted to reach -0.39 in one year’s time.
Technical Analysis of MaxCyte Inc (MXCT)
Let’s dig in a bit further. During the last 5-days, its volume was 0.8 million. That was better than the volume of 0.52 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 15.03%. Additionally, its Average True Range was 0.22.
During the past 100 days, MaxCyte Inc’s (MXCT) raw stochastic average was set at 0.78%, which indicates a significant decrease from 1.60% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 65.64% in the past 14 days, which was higher than the 56.89% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.77, while its 200-day Moving Average is $4.20. However, in the short run, MaxCyte Inc’s stock first resistance to watch stands at $3.38. Second resistance stands at $3.53. The third major resistance level sits at $3.62. If the price goes on to break the first support level at $3.15, it is likely to go to the next support level at $3.06. The third support level lies at $2.91 if the price breaches the second support level.
MaxCyte Inc (NASDAQ: MXCT) Key Stats
The company with the Market Capitalisation of 338.73 million has total of 105,483K Shares Outstanding. Its annual sales at the moment are 41,290 K in contrast with the sum of -37,920 K annual income. Company’s last quarter sales were recorded 8,160 K and last quarter income was -11,560 K.
